Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune (NASDAQ: ALT ) is a small-cap biotech company bringing a GLP-1/Glucagon dual-agonist peptide called Pemvidutide to market. The company has pivoted multiple times in its history but is now casting a stake in obesity and MASH markets. IntenseI am a corporate strategy professional with work experience across industrials, energy, and technology. My primary investment interest is in biotech where I have over a decade of investment experience. My secondary investment interests are in dividend growth equ ...